Neurex Corp. said Wednesday it licensed the worldwide rights (exceptGermany) to Corlopam (generic: fenoldopam) from SmithKlineBeecham.Paul Goodard, Nuerex's chairman and chief financial officer, toldBioWorld the terms of the cash, stock and royalty deal would not bedisclosed. But he said the deal is not expected to affect the Menlo Park,Calif., company's ability to fund the remainder of its clinical work.The compound, which has potent systemic and renal vasodilatingproperties, is a dopamine DA1 agonist.Corlopam is in Phase III trials as an intravenous treatment foraccelerated hypertension. Neurex expects the studies needed in order tofile for regulatory approval in the U.S. to be completed in 1995. Thecompound also has been targeted for indications including congenitiveheart failure and acute renal failure. _ Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.